Financial Performance - Net sales for Q3 2025 were $3.9 billion, a 6.9% decrease year-over-year, primarily due to a 10.6% decline in core organic net sales and commodity deflation of 1.1%[3] - Gross profit was $1.2 billion, down 13.5%, with a gross profit margin of 30.4%, a decrease of 240 basis points from the prior year[4] - Net income was $122.4 million, or diluted EPS of $1.10, representing a 57.0% decrease compared to $284.8 million, or $2.44 EPS, in the same period last year[9] - Adjusted EBITDA decreased 30.8% to $433.7 million, with an adjusted EBITDA margin of 11.0%, down 380 basis points year-over-year[3] - Free cash flow for the quarter was $464.9 million, a decrease of 26.8% from $634.7 million in the prior year period[3] - For the three months ended September 30, 2025, net sales were $3,941,190, a decrease of 6.9% compared to $4,232,494 in the same period of 2024[29] - Gross margin for the three months ended September 30, 2025, was $1,199,483, down from $1,386,333 in 2024, reflecting a decline of 13.5%[29] - Net income for the three months ended September 30, 2025, was $122,384, a decrease of 57.0% compared to $284,783 in 2024[29] - Adjusted EBITDA for the three months ended September 30, 2025, was $433.7 million, with an adjusted EBITDA margin of 11.0%[38] - Total net sales for the three months ended September 30, 2025, were $3,941.2 million, down 6.9% from $4,232.5 million in 2024[46] - Adjusted net income for the nine months ended September 30, 2025, was $645.8 million, compared to $1,107.4 million in 2024, reflecting a decline of approximately 41.7%[36] - Free cash flow for the nine months ended September 30, 2025, was $765.0 million, after capital expenditures of $256.1 million[45] Future Projections - The company expects full-year 2025 net sales to be in the range of $15.1 billion to $15.4 billion[12] - Projected adjusted EBITDA for 2025 is expected to be between $1.625 billion and $1.675 billion[12] - The company anticipates delivering $45 million to $60 million in productivity savings in 2025[13] Shareholder Actions - The company has repurchased 3.4 million shares year-to-date at an average price of $118.65 per share, totaling $403.6 million[13] Liquidity and Debt - Liquidity as of September 30, 2025, was approximately $2.1 billion, consisting of $1.8 billion in net borrowing availability and $0.3 billion in cash[13] - The company’s long-term debt, net of current maturities, increased to $4,428,746 as of September 30, 2025, compared to $3,700,643 as of December 31, 2024[33] - Interest expense for the three months ended September 30, 2025, totaled $69.9 million, with net debt outstanding at $4,191.7 million[43] Operational Metrics - The company reported net cash provided by operating activities of $547,724 for the three months ended September 30, 2025, compared to $729,958 in 2024, a decrease of 25.0%[31] - Total assets increased to $11,430,883 as of September 30, 2025, compared to $10,583,086 as of December 31, 2024, reflecting a growth of 8.0%[33] - Cash and cash equivalents at the end of the period were $296,162, a decrease from $328,103 at the end of the same period in 2024[31] - Selling, general and administrative expenses for the three months ended September 30, 2025, were $970,715, slightly up from $958,310 in 2024[29] - GAAP SG&A expense for the three months ended September 30, 2025, was $970.7 million, representing 24.6% of sales[41] Market Trends - The percentage of sales attributed to value-added products decreased to 47.1% in Q3 2025 from 49.7% in Q3 2024[46] - The company reported a decline in sales across multiple product categories, with manufactured products down 14.4% year-over-year[46] Tax and Accounting - The company’s effective tax rate on operations is forecasted to be impacted by various non-recurring items, making future estimates challenging[25] - Adjusted EBITDA outlook and free cash flow forecasts exclude certain income and expense items, which may include restructuring charges and non-recurring costs[25] - GAAP net income for the three months ended September 30, 2025, was $122.4 million, a decrease from $284.8 million in the same period of 2024[36] - Basic adjusted net income per share for the three months ended September 30, 2025, was $1.89, down from $3.09 in the same period of 2024[36]

Financial Performance - First Foundation Inc. reported a net loss of $146.3 million for Q3 2025, translating to a loss per share of ($1.78) [2] - Total revenue for Q3 2025 was $63.6 million, an increase from $51.4 million in the prior quarter [8] - Net interest income decreased to $46.1 million in Q3 2025, down from $50.1 million in the previous quarter [8] - Noninterest income was $17.5 million for the quarter, a significant increase from $1.3 million in the prior quarter [29] - The net loss for Q3 2025 was $(146.323) million, compared to a net loss of $(82.174) million in Q3 2024, indicating worsening financial performance [48] - Basic and diluted net loss per share for Q3 2025 was $(1.78), compared to $(1.23) in Q3 2024 [49] - Adjusted net income attributable to common shareholders was $(146,125) thousand for the quarter ended September 30, 2025 [61] - Adjusted return on average assets was (4.90)% for the quarter ended September 30, 2025 [62] Credit Losses and Provisions - The company recorded a provision for credit losses of $65.0 million during the quarter, raising the allowance for credit losses to 1.40% of loans held for investment [7] - Provision for credit losses increased to $65.045 million in Q3 2025, compared to $282 thousand in Q3 2024, indicating a rise in expected credit losses [48] - The allowance for credit losses on loans held for investment was $101.9 million, or 1.40% of total loans held for investment [39] - The allowance for credit losses to loans held for investment was 1.40%, up from 0.50% in the previous quarter [50] Assets and Liabilities - Total assets increased to $11.91 billion as of September 30, 2025, from $11.59 billion as of June 30, 2025 [47] - Total liabilities rose to $10.99 billion as of September 30, 2025, compared to $10.54 billion as of June 30, 2025 [47] - Average assets totaled $11.9 billion for the current quarter, down from $12.2 billion in the prior quarter [16] - Total loans outstanding as of September 30, 2025, were $7,296,895, a decrease of 3.25% from $7,542,865 in the previous quarter [53] Deposits and Funding - Total deposits increased to $9.3 billion as of September 30, 2025, compared to $8.6 billion at the end of the previous quarter [8] - Deposits increased to $9.29 billion as of September 30, 2025, up from $8.59 billion as of June 30, 2025 [47] - The loan to deposit ratio was 83.6% as of September 30, 2025, compared to 93.4% as of June 30, 2025 [5] Efficiency and Costs - The efficiency ratio improved to 90.0% in Q3 2025, down from 116.0% in the previous quarter [2] - Customer service costs decreased to $9.1 million in Q3 2025, down from $13.0 million in the prior quarter [8] - Total noninterest expense for Q3 2025 was $57.482 million, slightly down from $60.225 million in Q3 2024 [48] Equity and Book Value - Shareholders' equity decreased to $917.9 million as of September 30, 2025, from $1,050.6 million as of June 30, 2025, primarily due to a net loss of $146.3 million for the quarter [42] - The tangible book value per common share was $10.02 as of September 30, 2025, down from $11.65 as of June 30, 2025, reflecting a decline of 14.0% [42] - Book value per common share decreased to $11.10 in Q3 2025 from $12.75 in Q2 2025, a decline of approximately 13.0% [65] Mergers and Future Outlook - First Foundation announced a merger with FirstSun Capital Bancorp, expected to create a combined entity with $17 billion in assets [3] - The forward-looking statements indicate potential risks including credit losses and changes in economic conditions that could impact future financial performance [44]

Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update FLORHAM PARK, N.J., October 30, 2025 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "Our performance this quarter reinforces our belief in the strength of our GI-fo ...

Exhibit 99.1 Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance • Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOY • Conference Call Scheduled for Today at 8:00 A.M. Eastern Richmond, VA, October 30, 2025 – Indivior PLC (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update. "In the third quarter, we executed on Phase I of the Indivior Acti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37565 NovoCure Limited (Exact Name of Registrant as Specified in Its ...

Novocure Reports Third Quarter 2025 Financial Results Quarterly net revenues of $167 million, up 8% year-over-year, with 4,416 active patients on therapy as of September 30, 2025 Premarket approval application for Tumor Treating Fields therapy use in pancreatic cancer submitted and under substantive review by the U.S. Food and Drug Administration BAAR, Switzerland – Novocure (NASDAQ: NVCR) today reported financial results for the third quarter that ended September 30, 2025. Novocure is a global oncology com ...

| TABLE OF CONTENTS: Page: | | | --- | --- | | Production Volumes and Activity Summary | 2 | | Hedge Volumes and Pricing… | 3 | | Gas Hedging Gain/Loss Projections and Actuals | 4 | | Consolidated Statements of Income | 5 | | Consolidated Balance Sheets | 6 | | Consolidated Statements of Cash Flows… | 7 | | Market Mix and Natural Gas Price Reconciliation… | 8 | | Price and Cost Data (Per Mcfe) | 9 | | Guidance… | 10 | | Definitions | 11 | | Sales of Natural Gas, NGL and Oil, including Cash Settlements and N ...

Financial Performance - Third quarter consolidated revenues reached $7.6 billion, up from $6.49 billion in the same quarter of 2024, representing a year-over-year growth of approximately 17%[2] - Net income attributable to common stock for the third quarter was $339.4 million, or $2.24 per diluted share, compared to $293.2 million, or $1.95 per diluted share, in the prior year, reflecting a 15.7% increase in net income[2] - Adjusted EBITDA for the third quarter was $858.3 million, contributing to a record backlog of $39.2 billion, indicating strong demand in the Electric segment[2][3] - Revenues for Q3 2025 reached $7,631,408, a 17.5% increase from $6,493,167 in Q3 2024[26] - Gross profit for Q3 2025 was $1,216,434, up 20.2% from $1,012,570 in Q3 2024[26] - Net income attributable to common stock for Q3 2025 was $339,420, representing a 15.7% increase from $293,185 in Q3 2024[26] - Earnings per share (diluted) for Q3 2025 was $2.24, compared to $1.95 in Q3 2024, reflecting a 14.9% increase[26] - Operating income for Q3 2025 was $517,217, a 20% increase from $431,161 in Q3 2024[26] - Total revenues for the nine months ended September 30, 2025, were $20,637,749, a 20.5% increase from $17,119,373 in the same period of 2024[26] - The company reported a gross profit of $3,058,045 for the nine months ended September 30, 2025, up 24.9% from $2,447,395 in 2024[26] - Adjusted net income attributable to common stock for the nine months ended September 30, 2025, was $1.13 billion, compared to $0.89 billion for the same period in 2024[38] - Adjusted diluted earnings per share for the three months ended September 30, 2025, was $3.33, compared to $2.72 in 2024, reflecting a 22.5% increase[50] - EBITDA for the three months ended September 30, 2025, was $772,847, representing a 22% increase from $634,104 in 2024[50] Cash Flow and Expenditures - Year-to-date cash flow from operations totaled $1.1 billion, with free cash flow amounting to $726.3 million[2] - Free cash flow for the three months ended September 30, 2025, was $438,096, down from $539,470 in 2024, indicating a decrease of 18.7%[54] - Net cash provided by operating activities for the nine months ended September 30, 2025, was $1,102,405, a decrease of 19.5% from $1,369,181 in 2024[54] - Capital expenditures for the nine months ended September 30, 2025, totaled $415,560, down from $457,093 in 2024, a reduction of 9.1%[54] - Free cash flow for the full year 2025 is estimated to be between $1,300,000,000 and $1,700,000,000[68] - Net cash provided by operating activities is projected to range from $1,850,000,000 to $2,250,000,000 for the full year 2025[68] Future Projections - For the full year 2025, the company expects revenues between $27.8 billion and $28.2 billion, with net income projected between $987.1 million and $1.06 billion[12] - Adjusted diluted earnings per share for the full year 2025 are anticipated to range between $10.33 and $10.83, reflecting significant growth compared to previous periods[12] - Estimated adjusted net income attributable to common stock for the full year 2025 is projected to be between $1,562,600,000 and $1,637,400,000[60] - Estimated EBITDA for the full year 2025 is projected to be between $2,493,000,000 and $2,599,900,000[65] - Adjusted EBITDA for the full year 2025 is expected to range from $2,768,400,000 to $2,875,300,000[65] - Net income attributable to common stock (GAAP) is estimated to be between $987,100,000 and $1,061,900,000 for the full year 2025[65] Acquisitions and Market Expansion - Quanta completed five acquisitions in the first nine months of 2025, enhancing its operational capabilities and market reach[6] - The company has been selected by NiSource to provide power generation and grid infrastructure solutions capable of producing approximately 3 gigawatts of power for a large load customer[7][6] - The company is focused on expanding its total solutions platform to meet the growing demand for electricity driven by various sectors, including data centers and industrialization[6] Stock and Shareholder Returns - Quanta repurchased 538,559 shares of its common stock for $134.6 million, with approximately $365.1 million remaining under its stock repurchase program[8] - The weighted average diluted shares outstanding increased to 151,496 in Q3 2025 from 150,556 in Q3 2024[26] Segment Performance - Electric segment revenues accounted for 80.9% of total revenues in Q3 2025, generating $6.17 billion, compared to $5.23 billion in Q3 2024[30] - Operating income for the Electric segment was $703.84 million, with an operating margin of 11.4%, compared to $576.01 million and 11.0% in the prior year[30] - Remaining performance obligations for the Electric segment totaled $19.09 billion as of September 30, 2025, an increase from $15.65 billion at the end of 2024[37] - Total backlog increased to $39.17 billion as of September 30, 2025, compared to $34.54 billion at the end of 2024, reflecting a growth of 13.5%[37] - The Underground and Infrastructure segment generated revenues of $1.46 billion in Q3 2025, up from $1.26 billion in Q3 2024, representing a growth of 15.9%[30] Expenses and Costs - The provision for income taxes for Q3 2025 was $119,605, compared to $82,421 in Q3 2024, indicating an increase in tax expenses[26] - The company experienced a rise in selling, general and administrative expenses to $572,950 in Q3 2025, up from $483,878 in Q3 2024[26] - Corporate and non-allocated costs increased to $308.84 million in Q3 2025, compared to $238.81 million in Q3 2024, impacting overall operating income[30] - Acquisition and integration costs for the three months ended September 30, 2025, were $31,903, significantly higher than $7,053 in 2024[50] - Non-cash stock-based compensation for the nine months ended September 30, 2025, was $129,121, compared to $110,815 in 2024, reflecting a 16.5% increase[50] - Non-cash stock-based compensation is expected to be $177,200,000 for the full year 2025[65] - Acquisition and integration costs are projected to be $76,500,000 for the full year 2025[65] - Amortization of intangible assets is estimated to be $490,000,000 for the full year 2025[65]

Revenue Performance - For the three months ended September 30, 2025, the company generated $150.9 million in U.S. net product revenue from SYFOVRE, a slight decrease from $152.0 million in the same period of 2024[130]. - For the nine months ended September 30, 2025, the company reported $431.7 million in U.S. net product revenue from SYFOVRE, down from $444.0 million in 2024[130]. - EMPAVELI generated $26.8 million in U.S. net product revenue for the three months ended September 30, 2025, compared to $24.6 million in 2024[131]. - For the nine months ended September 30, 2025, EMPAVELI's U.S. net product revenue was $67.3 million, down from $74.7 million in 2024[131]. - Net product revenue for the three months ended September 30, 2025, was $177.8 million, a decrease of 0.7% from $176.6 million in the same period of 2024[178]. - Net product revenue for the nine months ended September 30, 2025, was $499.0 million, a decrease of 4% from $518.8 million in the same period of 2024[191]. Total Revenue and Income - For the three months ended September 30, 2025, total revenue increased by 133% to $458.6 million, compared to $196.8 million in the same period in 2024[177]. - Total revenue for the nine months ended September 30, 2025, increased by 41% to $803.9 million, compared to $568.8 million in 2024[190]. - Net income for the three months ended September 30, 2025, was $215.7 million, a significant increase compared to a net loss of $57.4 million in the same period in 2024, representing a 476% change[177]. - The company reported a net income of $81.3 million for the nine months ended September 30, 2025, compared to a net loss of $161.5 million in 2024, representing a significant turnaround[190]. Operating Expenses - Operating expenses decreased by 4% to $235.4 million, with cost of sales down by 27% to $24.5 million and research and development expenses down by 23% to $68.2 million[177]. - Research and development expenses decreased by 23% to $68.2 million for the three months ended September 30, 2025, from $88.6 million in 2024, mainly due to a reduction in program-specific external costs[184]. - Research and development expenses decreased by $29.6 million to $221.6 million for the nine months ended September 30, 2025, a decrease of 12% compared to $251.2 million for the same period in 2024[196]. - Selling, general and administrative expenses increased by 17% to $142.7 million for the three months ended September 30, 2025, from $122.0 million in 2024, attributed to higher general and administrative expenses[187]. - Selling, general and administrative expenses increased by $23.6 million to $403.2 million for the nine months ended September 30, 2025, an increase of 6% from $379.6 million in 2024[199]. Cash and Financing - As of September 30, 2025, the company had cash and cash equivalents of $479.2 million, including money market funds[221]. - The company expects to continue incurring expenses to support ongoing commercial activities related to product manufacturing and sales of EMPAVELI and SYFOVRE[215]. - The company anticipates that current cash and cash equivalents will be sufficient to fund projected operating expenses for at least the next 12 months[216]. - The company may need to finance its cash needs through external sources if sales of EMPAVELI and SYFOVRE are insufficient[218]. - The company has financed operations primarily through $2.6 billion in net proceeds from public offerings and $414.1 million in payments and royalties from Sobi[136]. Regulatory and Clinical Developments - The FDA approved EMPAVELI for the treatment of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in July 2025, based on a study showing a 68% reduction in proteinuria[131]. - The company expects to initiate two pivotal clinical trials for EMPAVELI by year-end 2025, targeting primary focal segmental glomerulosclerosis and delayed graft function[134]. Market Risks and Future Outlook - The company faces numerous risks and uncertainties in the commercialization of EMPAVELI and SYFOVRE, impacting future funding requirements[217]. - Future product development may be delayed or limited if the company cannot generate sufficient funds from sales or raise additional funds[219]. - The company is focused on establishing a commercial infrastructure and manufacturing capabilities to support the continued commercialization of its products[217]. - The company is unable to estimate increased capital outlays and operating expenses associated with research and commercialization due to various unknown factors[217]. - An immediate 10% change in interest rates would not materially affect the fair market value of the company's investment portfolio due to its low risk profile[221]. - The company is exposed to market risk related to changes in interest rates, which could impact its financial condition[221].

Exhibit 99.1 OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 BANNOCKBURN, IL., October 30, 2025 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (Year-over-year comparisons unless otherwise noted) John C. Rademacher, Chief ...